European Psychiatry - Volume 33 - March 2016

307 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348 S303
are sex hormones, thyroid hormones and prolactin. However, the
question whether there is an impact of the hormonal distur-
bances on cognitive functioning of schizophrenia patients is rarely
addressed.
Objective To assess the relationship between serum levels of hor-
mones and cognitive abilities in male schizophrenic patients.
Subjects and methods In the index group, there were 15
schizophrenia male patients, mean age 36. The control group
was formed by 15 healthy volunteers, mean age 36. In the two
groups, serum hormones levels were measured and neuropsy-
chological tests were performed. Analysed hormones included
thyroid-stimulating hormone (TSH), luteinizing hormone (LH),
follicle-stimulating hormone (FSH), estradiol, testosterone, proges-
terone and prolactin. Cognitive abilities were measured with the
following tests: Trail Making Test (TMT) Part A and B, Semantic
Category Fluency (SCF), Initial Letter Fluency (ILF) and Stroop Task
Part 1 and 2.
Results The levels of FSH, LH and testosterone were lower in
the index group than in the control group (3.01 mIU/mL vs 5.90
mIU/mL; 3.83 mIU/mL vs 5.28 mIU/mL; 2.76 ng/mL vs 4.69 ng/mL;
accordingly) while the level of prolactin was higher in the index
group (620 uIU/mL vs 118 uIU/mL). Patients performed worse that
controls in all neuropsychological tests. The differences in scores of
TMT Part B, ILF and Stroop Task Part 2were found to be statistically
significant.
Conclusions There was no significant relationship between
serum level of analysed hormones and performance on cognitive
tasks.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW533
Reaction time, processing speed and
sustained attention in patients with
schizophrenia: Impact on functioning
A. Orozco Vicens Ruiz ra˜nas Lahera ∗
1 Príncipe de Asturias university hospital, psychiatry, Alcalá-Madrid,
Spain
2 University of Alcalá- IRyCIS- CIBERSAM, medicine and medical
specialties, Madrid, Spain
∗ Corresponding author.
Introduction Some studies have related processing speed with
functionality. A more discriminative analysis of different compo-
nents of this neuropsychological construct is needed.
Objectives/Aims To measure the performance of a group of
patients with schizophrenia in reaction time, processing velocity
and sustained attention. To compare the impact on functioning of
these three measures.
Methods Ninety-eight outpatients between 18 and 65 years
diagnosed with schizophrenia, based on the DSM-V, with a 3-
month period of clinical stability, were recruited. Sociodemografic
and clinical data were collected: PANSS scale, Akathisia Simpson-
Angus Brief Scale, State-Trait Anxiety Inventory (STAI) and Global
Functioning Scale (GAF). The following variables were measured:
reaction time (SUPERLAB PRO), processing speed (TMT-A, subtest
of symbol coding BACS, verbal fluency) and sustained attention
(Continuous Performance Test).
Results Functionality of patients was correlated to Elective Reac-
tion Time (the subject must react to different types of stimuli and to
choose between several possible answers) [P = −0.205; P = 0.047],
but NOT with Simple Reaction Time [P= 0.109; P = 0.293)]. Func-
tionality was significantly correlated to Symbols Coding (P = 0.328;
P = 0.001), and a trend was observed regarding semantic fluency
(P = 0.190; P = 0.06) and the TMT-A (P =−0.179; P = 0.08). InCPT, Cor-
rect Detection was correlated with GAF score (P = 0.380; P = 0.000)
but not omission errors. The model of lineal regression shows a
differential impact of every measure in global functioning.
Conclusions Reaction time, processing speed and sustained
attention are different variables and each of them have impact on
functioning in schizophrenia.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW534
Monotherapy treatment with
cariprazine for the treatment of
predominant negative symptoms of
patients with schizophrenia:
A double-blind, active
comparator-controlled trial
G. Németh ∗, M. Debelle , I. Laszlovszky , E. Szalai ,
B. Szatmári , J. Harsányi , Á. Barabássy , S. Durgam , I. Bitter ,
S. Galderisi
1 Gedeon Richter Plc, medical division, Budapest, Hungary
2 Forest research institute, clinical development, Jersey City, USA
3 Semmelweis university, department of psychiatry and
psychotherapy, Budapest, Hungary
4 University of Naples SAN, psychiatry, Naples, Italy
∗ Corresponding author.
Objective To examine the effect of cariprazine, a dopamine D3/D2
receptor partial agonist with preferential binding to D3 receptors,
on predominant negative symptoms of schizophrenia.
Methods Subjects with schizophrenia and PANSS factor score
for negative symptoms (PANSS-FSNS) ≥ 24 and no pseudospecific
factors (e.g. extrapyramidal symptoms, depression) were random-
ized to cariprazine 4.5mg/d (dose range: 3-6mg/d) or risperidone
4mg/d (dose range: 3-6mg/d) for 6 months.
Results Four hundred and sixty-one patients were randomized
1:1 to double-blind risperidone (n = 231) or cariprazine (n = 230)
treatment. Change from Baseline (CfB) at week 26 in the primary
parameter, PANSS-FSNS, was larger in the cariprazine group than
in the risperidone group (LSMD = −1.47; 95% CI: [−2.39, −0.53];
P = 0.002) significant fromweek 14 onwards. CfB at week 26 in the
functional parameter, Personal and Social Performance (PSP) total
score, showed similarly greater improvementwith cariprazine than
risperidone (LSMD = 4.63; 95% CI: [2.71, 6.56]; P < 0.001) signifi-
cant from week 10 onward. Statistically significant differences in
favor of cariprazine at week 26 were shown in the PSP areas of
self-care, socially useful activities and personal and social relation-
ships. Most patients tolerated the study treatment well, as reflected
by low discontinuation rates due to adverse events (AEs). Adverse
event profiles of cariprazine and risperidonewere similar. Themost
common AEs during study treatment were insomnia (10.0%), and
headache (10.4%), both in the risperidone group.
Conclusion 26-week cariprazine treatment, given as antipsy-
chotic monotherapy, was significantly more effective on negative
symptoms and on functioning than risperidone in patients with
predominant negative symptoms of schizophrenia.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW535
Identification of subtypes of Chinese
schizophrenia patients before
discharge: A cluster analysis
S. Liu ∗, Z. Li
Peking Union Medical College, School of Nursing, Beijing, China
∗ Corresponding author.
Introduction People with schizophrenia is a highly heteroge-
neous group. Identifying subtypes of people with schizophrenia
before discharge may help develop targeted discharge plans.